Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.24 ▼ -0.11
(-2.53%)
MKT CAP: $2.53B • VOL: 20.96M
52W L $3 52W H $6
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$4
MEDIAN
$5
MEAN
$5
HIGH
$6
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RXRX TAPE
RXRX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $5.13 | $4.88 | 2025-02-14 | $3.86 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $5.34 | $5.00 | 2025-02-06 | $3.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $4.83 | $4.66 | 2025-01-29 | $4.07 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $4.32 | — | 2025-01-17 | $4.16 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $3.73 | $4.03 | 2025-01-09 | $3.77 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $5.05 | $4.41 | 2024-12-18 | $3.69 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $4.11 | $4.28 | 2024-12-04 | $3.94 | -4.3% | 48% | C |